News stories about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.9411949847774 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 20.25 on Friday. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $24.45. The company has a 50-day moving average of $21.32 and a 200 day moving average of $12.73. The stock’s market cap is $1.11 billion.
Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same period last year, the firm posted ($0.75) EPS. Equities analysts anticipate that Dynavax Technologies Corporation will post ($1.63) earnings per share for the current year.
A number of research firms have recently weighed in on DVAX. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $28.00 price target (up from $26.00) on shares of Dynavax Technologies Corporation in a research note on Monday, September 25th. Cantor Fitzgerald assumed coverage on shares of Dynavax Technologies Corporation in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 price objective on the stock. ValuEngine raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Finally, William Blair reaffirmed an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $25.00.
ILLEGAL ACTIVITY WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/27/dynavax-technologies-corporation-dvax-earning-somewhat-positive-news-coverage-study-finds.html.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.